AI-Powered Precision Medicine
Decoding Cancer Evolution
Defining the Future of Care
Dynamic, interpretable, AI-powered biomarkers that predict treatment response and outsmart resistance.
AI-Powered Precision Medicine
Dynamic, interpretable, AI-powered biomarkers that predict treatment response and outsmart resistance.
Gaps in medicine we solve
We turn fragmented data into continuous, personalized treatment intelligence.
Track treatment response in real time—without invasive procedures.
Integrate genomic, clinical, and longitudinal data into one view.
Reveal the biological drivers behind every prediction.
Identify responders early and guide go/no-go decisions with confidence.
Unravel Genomics Differentiators
We unify imaging, genomics, and clinical data to predict response, resistance, and evolution in real time.
Tumor evolution
Treatment response
Resistance mechanism
We built a computational framework that enables each step of personalized medicine, from multi-modal data integration to biomarker development to forecasting cancer outcomes, delivered as actionable clinical reports that guide therapy decisions.
While MRD and risk scores look backward, we deliver forward-looking therapy selection and resistance-blocking insight for any cancer type.
We deliver target identification, early activity/futility markers, and smarter trial designs that reduce risk, sample size, and time.
Our Platform
Intelligence Layer
From multi-modal data integration to biomarker development to forecasting cancer outcomes, delivered as actionable clinical reports.
Learn MoreEndorse bx
Uses RNA/DNA-seq from tumor biopsy to stratify patients by endocrine therapy response at any disease stage. Fully interpretable, clinic-ready, automated biopsy-to-report pipeline.
Learn MoreIntroducing Unravel Journey
AI-powered genomic biomarker monitoring — from wellness tracking to cancer signal detection — with your personalised AI Care Plan. Cancer Journey adds EndorseScore, Immune score, and mTOR-Score with longitudinal cancer trajectory.
Wellness Journey
Annual AI biomarker test + AI-reviewed Care Plan
Cancer Journey
Bi-annual testing + cancer signal monitoring
Our Science
Published in Nature Cancer, Nature Communications, and Molecular Systems Biology.
Nature Communications
Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers
2025
Molecular Systems Biology
Blocking cancer-fibroblast mutualism inhibits proliferation of endocrine therapy resistant breast cancer
2025
Nature Communications
Cell facilitation promotes growth and survival under drug pressure in breast cancer
2023
Molecular Systems Biology
ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers
2022
Nature Cancer
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy
2021
Explore Unravel
Meet the core team
Chief Executive Officer
Experienced visionary leader in emerging biomedical technologies for precision health and early cancer detection.
Founder & President
Leader in translational medicine and systems biology with a track record spanning industry, academia & government. Built and managed $500M+ precision oncology programs.
Founder & VP
Expert in AI/ML-based biomarker development with a track record of translating algorithms into clinical practice.
Chief Scientific Officer
Over a decade leading computational genomics, mathematical modeling of cancer, and translational studies.
Partner with Unravel Genomics to leverage dynamic, AI-powered biomarkers for treatment response prediction and resistance management.